Contacts

 MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000 

July 28, 2022

 > The product would be commercialized under the brand name UZEDY 


Kåre Schultz, CEO of Teva, spoke today at the Q2 earnings call of Teva:
Answering questions from participants, M. Schultz said: “We still expect to launch UZEDY, which is the brand name for the risperidone LAI, first half of next year.”
He added later that this “risperidone long-acting product looks extremely good from a clinical point of view, both in terms of efficacy and safety”, and that “it will be a major improvement compared to long acting antipsychotics that you can do subcutaneously, and it works for one or two months. So that is going to be really nice to get that finally approved and launched next year.”

Session en français

Rendez-vous le mardi 14 juin à 18h30 (CEST) pour une vidéoconférence dédiée aux résultas annuel 2021-2022

English session

On Tuesday 14, June at 7.30 pm (CEST) participate in our videoconference dedicated to our Financial year 2021-2022 results

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.